Sökning: onr:"swepub:oai:DiVA.org:oru-101484" >
I-CARE, a European ...
I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease
-
- Peyrin-Biroulet, Laurent (författare)
- University of Lorraine, Nancy, France; Nancy University Hospital, Nancy, France
-
- Rahier, Jean-François (författare)
- Université catholique de Louvain, Yvoir, Belgium
-
- Kirchgesner, Julien (författare)
- Sorbonne Université, Paris, France
-
visa fler...
-
- Abitbol, Vered (författare)
- Hopital Cochin, Paris, France; Université Paris Cité, Paris, France
-
- Sebastian, Shaji (författare)
- Hull University Teaching Hospitals, Hull York, UK; Medical School/ University of Hull, Hull, UK
-
- Armuzzi, Alessandro (författare)
- Research Hospital, Rozzano, Italy; Humanitas University, Milan, Italy
-
- Karmiris, Konstantinos (författare)
- Venizeleio General Hospital, Heraklion, Greece
-
- Gisbert, Javier P. (författare)
- Hospital Universitario de La Princesa, Madrid, Spain; Universidad Autónoma de Madrid (UAM), Madrid, Spain
-
- Bossuyt, Peter (författare)
- Imelda General Hospital, Bonheiden, Belgium
-
- Helwig, Ulf (författare)
- University of Kiel, Kiel, Germany
-
- Burisch, Johan (författare)
- Copenhagen University Hospital, Copenhagen, Denmark
-
- Yanai, Henit (författare)
- Rabin Medical Center, Petah-Tikva, Israel; Tel Aviv University, Tel Aviv, Israel
-
- Doherty, Glen A. (författare)
- St. Vincent's University Hospital, Dublin, Ireland; University College Dublin, Ireland,INITIative IBD research network
-
- Magro, Fernando (författare)
- Centro Hospitalar Universitário de São João, Porto, Portugal; Universidade do Porto, Porto, Portugal
-
- Molnar, Tamás (författare)
- University of Szeged, Szeged, Hungary
-
- Löwenberg, Mark (författare)
- Amsterdam University Medical Center, Amsterdam, The Netherlands
-
- Halfvarson, Jonas, 1970- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology
-
- Zagorowicz, Edyta (författare)
- The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
-
- Rousseau, Hélène (författare)
- Nancy University Hospital, Vandoeuvre-lès-Nancy, France
-
- Baumann, Cédric (författare)
- Nancy University Hospital, Vandoeuvre-lès-Nancy, France
-
- Baert, Filip (författare)
- AZ Delta Hospital, Roeselare, Belgium
-
- Beaugerie, Laurent (författare)
- Sorbonne Université, Paris, France
-
I-CARE Collaborator Group, - (bidragsgivare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2023
- 2023
- Engelska.
-
Ingår i: Clinical Gastroenterology and Hepatology. - : Elsevier. - 1542-3565 .- 1542-7714. ; 21:3, s. 771-788.e10
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND AND AIMS: There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE was to assess prospectively safety concerns in IBD, with specific focus on the risk of cancer/lymphoma and serious infections in patients treated with for anti-tumor necrosis factor and other biologics monotherapy as well as in combination with immunomodulators.METHODS: I-CARE was designed as a European prospective longitudinal observational multicenter cohort study, to include patients with a diagnosis of Crohn's disease, ulcerative colitis or IBD unclassified established at least 3 months prior to enrollment.RESULTS: A total of 10,206 patients were enrolled between March 2016 and April 2019, including 6,169 (60.4%) patients with Crohn's disease, 3,853 (37.8%) with ulcerative colitis, and 184 (1.8%) with a diagnosis of IBD unclassified. Thirty-two percent of patients were receiving AZA/thiopurines, 4.6% 6-mercaptopurine, and 3.2% methotrexate at study entry. At inclusion, 47.3% of patients were treated with an anti-tumor necrosis factor agent, 8.8% with vedolizumab, and 3.4% with ustekinumab. Roughly one quarter of patients (26.8%) underwent prior IBD related surgery. Sixty-six % of patients had been previously treated with systemic steroids. Three percent of patients had a medical history of cancer prior to inclusion, and 1.1% had a history of colonic, esophageal or uterine cervix high-grade dysplasia.CONCLUSION: I-CARE is an ongoing investigator-initiated observational European prospective cohort study that will provide unique information on the long-term benefits and risks of biological therapies in IBD patients.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Nyckelord
- I-CARE
- biologics
- cancer
- efficacy
- inflammatory bowel disease
- lymphoma
- safety
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Peyrin-Biroulet, ...
-
Rahier, Jean-Fra ...
-
Kirchgesner, Jul ...
-
Abitbol, Vered
-
Sebastian, Shaji
-
Armuzzi, Alessan ...
-
visa fler...
-
Karmiris, Konsta ...
-
Gisbert, Javier ...
-
Bossuyt, Peter
-
Helwig, Ulf
-
Burisch, Johan
-
Yanai, Henit
-
Doherty, Glen A.
-
Magro, Fernando
-
Molnar, Tamás
-
Löwenberg, Mark
-
Halfvarson, Jona ...
-
Zagorowicz, Edyt ...
-
Rousseau, Hélène
-
Baumann, Cédric
-
Baert, Filip
-
Beaugerie, Laure ...
-
I-CARE Collabora ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Gastroenterologi
- Artiklar i publikationen
-
Clinical Gastroe ...
- Av lärosätet
-
Örebro universitet
-
Karolinska Institutet